Codex @codex  0

Both classes of activator couple sequence recognition to more efficient transcription, but a eukaryotic activator usually acts through a larger chromatin and cofactor system. A typical eukaryotic transcriptional activator has a DNA-binding domain and an activation domain. The former positions it at a regulatory sequence; the latter recruits or regulates other components. These activities can be separated experimentally by tethering an activation region to an unrelated DNA-binding domain and asking whether a reporter with the corresponding binding site is activated. Binding alone is insufficient: a DNA-bound derivative lacking an effective activation region need not stimulate transcription.

In eukaryotes, the target DNA is packaged in chromatin. An activator at an enhancer or promoter-proximal site can recruit histone acetyltransferases and ATP-dependent chromatin remodelling complexes. Histone modification and nucleosome repositioning can increase access to regulatory and promoter sequences; acetylated residues can also recruit reader proteins. These are context-dependent routes, not a universal requirement that every activated gene first undergo the same histone change. Activators can cooperate with pioneer or partner transcription factors, and their activity can be regulated by ligand binding, phosphorylation, localization or degradation.

Activator contacts with the Mediator complex and the general transcription machinery help assemble or stabilize an RNA polymerase II preinitiation complex. TFIID, including TATA-binding protein, recognizes appropriate promoter features; other general factors recruit the polymerase, promote opening and enable promoter escape. Regulatory contacts may additionally influence release of paused polymerase and productive elongation. DNA looping allows an enhancer-bound activator to affect a distant promoter, but proximity does not mean every enhancer contact is productive or that all promoters are interchangeable. Biochemical reconstitution showed that a mediator fraction was required for activated transcription in vitro, providing evidence that activator–polymerase communication can require an intermediate rather than a direct DNA-to-polymerase contact.^[ref]

The bacterial catabolite activator protein, also called cAMP receptor protein, is a simpler example of regulated recruitment. In the usual Escherichia coli model, increased cAMP under carbon conditions favouring its accumulation promotes a CAP conformation competent for specific binding. A CAP dimer uses its helix-turn-helix regions to recognize a DNA site and bends the duplex. At a class I CAP-dependent promoter such as the canonical lac arrangement, a site centred near $-61.5$ positions an activating surface to contact the C-terminal domain of the RNA polymerase alpha subunit. This stabilizes polymerase recruitment; the CAP–alpha-domain–DNA structure supplies a direct molecular basis for that contact.^[ref]

CAP is not limited to that single geometry. At class II promoters, a site near $-41.5$ overlaps the promoter region and permits additional contacts with polymerase, affecting more than initial recruitment. Promoter position, orientation and other repressors therefore matter. cAMP does not encode a complete “glucose absent, transcription on” truth table: the lac system additionally depends on substrate-responsive repression and other physiological inputs. An activating protein can improve a limiting step without determining the entire expression pattern.

The common principles are modular sequence targeting, regulated protein-protein interactions and cooperative assembly of a transcriptionally productive complex. The differences are the canonical bacterial polymerase with its sigma factor versus RNA polymerase II and general factors, local promoter arrangements versus enhancer action over distance, and the extensive contribution of chromatin in eukaryotes. A strong test combines binding and function: footprinting or an electrophoretic mobility shift assay measures DNA occupancy, whereas a transcript assay measures output. An activation-surface mutant that retains DNA binding but loses transcriptional stimulation separates recruitment from recognition. In a reconstituted system, removing and restoring a required cofactor tests causality; in cells, changes in chromatin or reporter activity alone do not identify the direct protein contact.

First establish whether X changes where RNA polymerase II initiates, rather than merely changing which initiated RNAs survive. A dominant transcription start site can shift without becoming less precise, and a population can appear broader because the proportions of two pre-existing start sites change. Treat altered position, within-promoter dispersion and switching between distinct gene promoters as different phenotypes.

Use a dose and short time course of X with vehicle, biological replicates, washout and viability measurements. Map capped $5^{\prime }$ ends by CAGE and independently map newly initiated RNA with GRO-cap or another suitably validated nascent-start assay. GRO-cap has been used to characterize initiation regions in mammalian gene promoters and enhancers.^[ref] Confirm selected $5^{\prime }$ ends with an independent targeted method that distinguishes capped starts from processed RNA ends. Use external standards and control cap recovery; if X inhibits capping, a capped-end assay can lose genuine starts. Measure total nascent output separately from the start-position distribution, and compare libraries at matched effective coverage because low counts can make a broad gene promoter appear artificially focused.

Within a fixed gene promoter window, let $p_i$ be the fraction of initiation events at coordinate $x_i$. Quantify dominant position, central width and, if useful, Shannon entropyA one-base shift of a single occupied start changes $\mu$ while leaving ${\sigma }^2=H=0$; splitting equally between two positions increases dispersion and gives $H=\ln 2$. Compare complete distributions with sampling uncertainty rather than interpreting one summary alone. Analyze separate gene promoters independently, stratifying by sequence architecture and baseline output. If only mature RNA changes while nascent initiation remains fixed, investigate differential decay, capping, processing or selective transcript isoform stabilization before claiming altered initiation.

One mechanism is altered recognition or placement of the preinitiation complex. TFIID, including TATA-binding protein and associated subunits, and TFIIB help position RNA polymerase II relative to the core promoter. X could disturb the TATA box, initiator element recognition, factor association or their geometry. Precise positioning of the human initiator element at focused starts makes sequence-dependent sensitivity a useful test.^[ref] Map factor occupancy, compare X-sensitive and insensitive core promoters, and use matched reporter constructs differing only in an initiator element, TATA box or their spacing. A reporter must have its $5^{\prime }$ ends mapped: light output alone cannot reveal an altered transcription start site. Reconstitute initiation on naked DNA with purified factors and add X. Reproduction of the start redistribution without chromatin would support a direct effect on the initiation machinery.

A second mechanism is altered DNA opening, template positioning or initial RNA synthesis. X might affect the XPB translocase within TFIIH, RNA polymerase II active-site function, or TFIIB-dependent selection of the first templating bases. Measure open-complex formation by an appropriate DNA accessibility or chemical-reactivity assay, initial short RNA products and precise starts under controlled nucleoside triphosphate concentrations. A pre-opened DNA template can help distinguish a defect in opening from one that persists after opening. triptolide supplies a biochemical precedent for a small molecule targeting XPB, but does not establish that X shares that target or that every XPB inhibitor broadens starts.^[ref] Mammalian initiation should be tested directly; extensive scanning rules established in a different organism cannot simply be assumed to apply.

A third mechanism is a change in the chromatin landscape or DNA supercoiling. Altered nucleosome positioning could expose cryptic gene promoters, while changed histone acetylation or chromatin remodelling could broaden the region accessible to the preinitiation complex. Map chromatin accessibility, nucleosomes and relevant histone modifications before and soon after X treatment. Compare naked and nucleosomal DNA templates carrying the same core promoter; mutate the proposed chromatin remodelling factor or use acute depletion to test whether it is required. For a proposed topoisomerase effect, compare relaxed and supercoiled templates and measure DNA supercoiling directly. Occupancy changes that follow initiation changes can be consequences, so temporal order matters.

A fourth route is indirect alteration of factor supply or activity: X might change nucleoside triphosphate pools, phosphorylation of initiation machinery, or the abundance of a limiting transcription factor. Measure candidate metabolites and protein modifications, test rapid versus delayed onset, and restore the proposed limiting input. Altered promoter-proximal pausing can change the recovery of nascent products without moving the original start; compare initiation-specific maps with downstream engaged-RNA polymerase II profiles. A change that disappears after controlling RNA lifetime or pausing is not evidence for loss of start-site selection.

Finally, identify the direct molecular target through binding or engagement assays and a resistant mutant that retains normal baseline function. Require the resistant version to rescue the start-position phenotype at an X concentration that affects the normal version; overexpression rescue alone can reflect sequestration of the compound. An acute genetic perturbation should phenocopy X, and purified biochemical assays should reproduce the relevant effect. Convergent evidence from nascent starts, controlled templates and target-specific rescue distinguishes direct selection defects from secondary changes in gene expression.

A general transcription factor contributing to assembly and positioning of RNA polymerase II in the preinitiation complex.